Nektar Therapeutics reported $10.86M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
ALKERMES USD 480.13M 15.88M Sep/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Amgen USD 10.4B 300M Sep/2026
Baxter International USD 2.98B 20M Sep/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Biogen USD 2.8B 60M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cipla INR 74.04B 2.85B Sep/2026
Dr.Reddys Laboratories INR 86.98B 6.27B Sep/2026
Eisai JPY 235.63B 1.3B Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Exelixis USD 658.69M 30M Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Grifols EUR 2B 306.7M Mar/2026
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
Incyte USD 1.56B 110M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Ironwood Pharmaceuticals USD 113.04M 6.53M Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
MacroGenics USD 32.83M 12.03M Jun/2026
Merck USD 18.1B 1.5B Sep/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Novartis USD 14.52B 112M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Takeda JPY 1.19T 32.9B Sep/2026
Teva Pharmaceutical Industries USD 4.37B 8.3B Sep/2026
Xencor USD 116.52M 65.3M Sep/2026